Matinas Topline Results of LYPDISO™ Against Vascepa Positive

 – LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® –

– LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction –

– Primary endpoint of percent change from baseline to end of treatment in triglycerides in the pharmacodynamic population did not meet statistical significance over Vascepa® –

– Per protocol analysis demonstrated statistical significance and superiority vs. Vascepa® on several key lipid and inflammatory markers –

– Management to host conference call today, Monday, February 1, 2021 at 8:00 a.m. ET –

The conference call can be accessed by dialing 877-407-5976 for participants in the U.S. or Canada and 412-902-0031 for international callers (reference passcode 13715418).

The conference call will also be webcast live on Matinas' website, www.matinasbiopharma.com, under the ‘Investors’ section and will be archived there for 90 days.

https://www.globenewswire.com/news-release/2021/02/01/2167088/0/en/Matinas-BioPharma-Announces-Topline-Results-from-ENHANCE-IT-Study-of-LYPDISO-Against-Vascepa.html